HSBC Maintains Hold on Bristol-Myers Squibb, Raises Price Target to $65
HSBC analyst Rajesh Kumar maintains Bristol-Myers Squibb (NYSE:BMY) with a Hold and raises the price target from $60 to $65.
An analyst at a big bank thinks Bristol-Myers Squibb is worth more money now, but still says to wait and not buy yet. This shows the company might be getting stronger, but the analyst isn't excited enough to say it's a great time to jump in.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.